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Purpose: Diseased corneas are potential targets for viral-based gene therapy to normalize (stimulate or inhibit) the
expression of specific proteins. The choice of viral vectors is important to achieve optimal effect. The purpose of this
study was to compare the tropism to different corneal cells of recombinant adenovirus (rAV) and recombinant adeno-
associated virus (rAAV) constructs using live rabbit and organ-cultured human corneas.
Methods: rAV constructs harbored the green fluorescent protein (GFP) gene under the control of major immediate early
cytomegalovirus (CMV) promoter. rAAV constructs from virus serotypes 1, 2 5, 7, and 8 had GFP under the chicken β-
actin promoter and CMV enhancer. For organ culture, 16 healthy and diabetic postmortem human corneas were used.
Five or fifteen μl rAV at 107 plaque forming units per 1 μl were added for 2 days to culture medium of uninjured corneas
that were further cultured for 5–32 days. rAAV were added at 1.2–7.8×1010 vector genomes per cornea for 3 days to each
cornea;  the  culture  then  continued  for  another  14–23  days.  Corneal  cryostat  sections  were  examined  by
immunohistochemistry. Live rabbit corneas were used following excimer laser ablation of the corneal epithelium with
preservation of the basal cell layer. Equal numbers of rAAV particles (2x1011 vector genomes) were applied to the cornea
for 10 min. After seven days to allow for corneal healing and gene expression the animals were euthanized, the corneas
were excised, and sections analyzed by immunohistochemistry.
Results: By direct fluorescence microscopy of live organ-cultured human corneas GFP signal after rAV transduction was
strong in the epithelium with dose-dependent intensity. On corneal sections, GFP was seen in all epithelial layers and
some endothelial cells but most keratocytes were negative. In rAAV-transduced organ-cultured human corneas GFP signal
could only be detected with anti-GFP antibody immunohistochemistry. GFP was observed in the epithelium, keratocytes,
and endothelium, with more pronounced basal epithelial cell staining with rAAV1 than with other serotypes. No difference
in the GFP expression patterns or levels between normal and diabetic corneas was noted. The rabbit corneas showed very
similar patterns of GFP distribution to human corneas. With all rAAV serotype vectors, GFP staining in the epithelium
was significantly (p=0.007) higher than the background staining in non-transduced corneas, with a trend for rAAV1 and
rAAV8 to produce higher staining intensities than for rAAV2, rAAV5 (p=0.03; rAAV5 versus rAAV1), and rAAV7.
rAAV serotype vectors also transduced stromal and endothelial cells in rabbit corneas to a different extent.
Conclusions: rAAV appears to reach many more corneal cells than rAV, especially keratocytes, although GFP expression
levels were lower compared to rAV. rAV may be more useful than rAAV for gene therapy applications requiring high
protein expression levels, but rAAV may be superior for keratocyte targeting.
Inherited, iatrogenic, and metabolic corneal diseases are
commonly encountered and present serious clinical problems,
often calling for corneal transplantation. Some of them have
a known underlying gene defect, best exemplified by a group
of dystrophies caused by a mutation in transforming growth
factor-β-induced gene, TGFBI/BIGH3 [1-4]. Other diseases,
like  keratoconus,  also  have  a  genetic  component,  but  the
altered gene(s) still remains unknown [5,6]. Many of these
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disorders  could  be  potentially  treated  by  supplying  a
functional gene or changing the expression levels of specific
genes in specific cells [7,8]. Another potential area of corneal
gene therapy application is treatment of fibrotic disorders and
of corneal haze after refractive procedures [7,9,10]. Our data
suggested the importance of altered expression of proteinases
and growth factors in diabetic corneas [11-13], which could
also be potentially corrected by gene therapy to alleviate the
symptoms of diabetic keratopathy.
In recent years, viral and non-viral gene therapy has been
successfully  attempted  for  delivering  genes  into  corneal
epithelial, stromal, and endothelial cells [14-20]. Although
most studies used reporter genes, such as green fluorescent
protein  (GFP),  some  groups  showed  improved  corneal
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2087parameters  after  alkali  burns  or  reduction  of  pathological
neovascularization  after  introduction  of  specific  genes  of
interest [19,21].
The advantage of viral-based therapies is that viruses
easily  enter  the  cells,  are  more  efficient  than  other  gene
delivery vehicles, and enable good expression of secreted
proteins  [22-24].  Recombinant  adenovirus  (rAV),  adeno-
associated virus (rAAV), herpes simplex virus type 1, and
lentiviruses are commonly used viral vectors. It has been
emphasized  that  some  viral  vector  treatments  induce
unacceptable  immune  responses,  inflammation,  and  virus
integration  into  the  host  genome,  with  unpredictable
consequences [25,26]. However, recently introduced new-
generation recombinant viruses combine long-term effects,
high gene transfer efficiency, and the ability to transfect non-
dividing cells with lack of a significant immune response.
They  are  rapidly  becoming  vehicles  of  choice  for  gene
therapy. The on-off mechanisms also allow time-controlled
action of viral vectors [27]. Viral vectors have been used to
deliver  specific  genes  with  high  efficiency  to  eye  tissues
including cornea [14,19,28,29].
Recent studies of rAAV-driven gene transduction found
that the preferential tissue site for expression and its relative
levels  were  dependent  on  virus  serotype  and  route  of
administration  [30-32].  It  seems,  therefore,  important  to
optimize viral vectors for each tissue of interest in terms of
cell  tropism  and  expression  levels.  The  main  goal  of  the
present work was to compare the corneal cell tropism and
levels of reporter protein GFP expression driven by different
strains of rAAV or rAV. In situ localization of transgene
expression  in  corneal  tissue  might  provide  guidelines  for
selecting the correct viral vector to transduce the cell type of
interest.  Two  different  systems  were  used  for  rAAV
transduction, rabbit eyes and human corneal organ cultures.
For  rAV,  only  human  corneal  organ  cultures  were  used
because this vector has been previously evaluated in the rat
eye model in the same way as has been done here in the rabbit
eyes [33]. The presented results show that rAV ex vivo mostly
infects epithelial and also endothelial cells, whereas rAAV
can infect most or all corneal cells both in vivo and ex vivo.
METHODS
Production of rAAV serotype vectors: Recombinant AAV
pseudo-serotypes 1, 2, 5, 7, and 8 were constructed by using
ITR and Rep from serotype 2 AAV and capsid protein from
serotypes 1, 2, 5, 7, and 8, respectively [34-37]. All rAAV
vectors (serotypes 1, 2, 5, 7, and 8, and true type 2) harbor the
GFP  gene  driven  by  chicken  β-actin  promoter  and
cytomegalovirus  (CMV)  enhancer.  AAV  purification  was
performed as previously described [38,39].
Production of rAV vectors: The coding region of GFP was
cloned into the unique BamHI restriction site of the transfer
vector pAL119 under the control of immediate early CMV
promoter  and  upstream  of  a  polyadenylation  signal  on  a
HindIII flanked expression cassette. The orientation of the
cloned transgene was determined by restriction analysis [40].
rAV  was  generated  by  homologous  recombination  in
HEK-293  cells  following  co-transfection  of  the  GFP-
harboring shuttle vector pAL119 with the plasmid pJM17
(Microbix  Biosystems,  Toronto,  Canada)  by  calcium
phosphate  co-precipitation  [40,41].  Homologous
recombination resulted in the generation of the replication
deficient rAV vector. rAV was propagated in HEK-293 cells,
purified twice on CsCl2 gradients, and dialyzed twice against
10 mM Tris-HCl pH 7.5, 1 mM MgCl2, 135 mM NaCl, and
once against the same buffer with 10% glycerol. The virus was
titrated by plaque assay on HEK-293 cells. Usually, viral titers
are  1011-1012  plaque-forming  units  per  ml  (pfu/ml).  GFP
staining appears to be dependent on virus dose, with most
intense staining at doses of 108 to 109 pfu/ml.
Rabbit eye model: The delivery efficiency of a transgene
packaged in different rAAV serotypes was tested in live rabbit
corneas. Adult New Zealand white rabbits were used for this
study and the procedure was performed in accordance to the
animal  care  guidelines  published  by  the  Institute  for
Laboratory Animal Research (Guide for the Care and Use of
Laboratory Animals). Briefly, rabbits were anesthetized with
isofluorane/oxygen inhalation, proparacaine eye drops were
applied to achieve local anesthesia of corneas, and both eyes
of each rabbit were ablated to a depth of 25 μm with a VISX
20/20  excimer  laser,  creating  a  6.5  mm  diameter  central
epithelial injury. The ablation conditions were specifically
designed not to remove all of the corneal epithelial cell layers,
but to only ablate to the basal cell layer. This procedure was
exactly like the one described previously for rat eyes treated
with  rAV  [33].  The  intention  was  to  transduce  the  basal
epithelial  cells  and  the  stromal  fibroblasts  by  topical
application of rAAV vectors. The ablated areas of both eyes
of each rabbit were then exposed for 10 min to 2×1011 rAAV
vector genomes applied on the cornea in phosphate buffered
saline in a 10 mm diameter vacuum trephine, which contained
the rAAV vector. Overall, two rabbit corneas were treated
with each of the rAAV vector serotypes.
Seven days after excimer laser ablation and transduction
by  rAAV  vectors,  the  animals  were  euthanized,  and  the
corneas were briefly fixed in situ by flooding the eye with 4%
p-formaldehyde. Corneas were then excised, fixed overnight,
embedded in Tissue Tek OCT Compound (Sakura Finetek,
Torrance, CA) and frozen by dipping into liquid nitrogen-
cooled isopentane. Tissue sectioning was performed with a
Microm H550 cryostat (Microm, Walldorf, Germany) and
10 μm sections were mounted on Superfrost/Plus microscope
slides  (Fisher  Scientific,  Pittsburgh,  PA)  for
immunohistochemistry.  Indirect  immunostaining  was
performed using chicken anti-GFP (Millipore, Temecula, CA)
followed  by  a  biotinylated  secondary  antibody  (Promega,
Madison, WI). Two types of signal detection systems were
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Burlingame,  CA)  was  used  for  light  microscopy  with
NovaRed  substrate  (Vector  Laboratories).  Alkaline
phosphatase  detection  system  with  VectorRed  substrate
(Vector Laboratories) was used in the fluorescent regime with
a Leica TCS SP2 AOBS Spectral Confocal Microscope (Leica
Microsystems, Bannockburn, IL).
For the quantification of GFP expression from different
serotypes of rAAV in rabbit cornea, bright-field micrographs
were taken for each section using a morphometric microscope,
with the same setting at the same day at a magnification of
20X,  and  the  relative  level  of  GFP  immunostaining  was
measured using MCID software (InterFocus Imaging, Linton,
UK). Basically, sampling tools of MCID were used to trace
the epithelial region of each image, and the semiquantitative
densitometry function was used to evaluate the opacity of the
selected region. After averaging the score from images of each
treatment, the score for background (control treatment) was
subtracted  to  generate  the  chart  in  Figure  1.  Levels  of
immunostaining  determined  by  the  MCID  software  were
analyzed for statistical significance by ANOVA followed by
the LSD post-hoc test using Statistica™ software (StatSoft®,
Tulsa, OK).
Corneal  organ  culture:  Normal  and  diabetic  postmortem
organ-cultured human corneas (a total of 16) were used. These
were obtained from National Disease Research Interchange
(NDRI, Philadelphia, PA). NDRI has a managerial committee
that operates under NIH oversight. It ensures adequate donor
family consent and patient information protection, as well as
compliance with human subject regulations. Both normal and
diabetic corneas were included because potential viral gene
therapy  for  diabetic  keratopathy  necessitates  comparative
testing  of  different  transduction  vectors  to  optimize  the
conditions  of  gene  delivery.  Cultures  were  initiated  and
maintained as described previously, in serum-free medium at
the air-liquid interface [42]. After 2–3 days in culture, viral
constructs harboring GFP were added to the corneas. Because
rAV titer may influence reporter gene expression [43], two
Figure 1. Quantitation of the GFP intensity of staining in corneal
epithelium.  The  strongest  signal  is  observed  with  rAAV1  and
rAAV8, with other serotypes being weaker. The asterisk indicates a
p=0.03 (rAAV5 versus rAAV1).
titers  were  used  (0.5×108  and  1.5×108  pfu  per  cornea);
however, they produced similar results (data not shown). Two
non-diabetic corneas each from two different donors received
the lower dose, and another two, the higher one. Virus was
incubated  for  2  days  in  culture  medium  with  uninjured
corneas, which were further cultured for either 5 days (for
efficiency assessment) or 32 days (for duration of detectable
expression). rAAV constructs from virus serotypes 1, 2, and
8 were used and were the same as in the rabbit model. For each
serotype, four organ-cultured corneas were used from four
different  donors  including  two  non-diabetics  and  two
diabetics. rAAV vectors were added to corneas for 3 days at
7.8×1010 vector genomes per cornea for rAAV1, 3.5×1010 for
rAAV2, and 1.2×1010 or 2.4×1010 for rAAV8 (in the range
published previously [35]). The medium was then changed
and the culture was continued for another 14 to 23 days, to
assess transduction efficiency of corneal cells at different time
points within the reported range of detectable GFP expression
[7,33]. This was important to determine a potential therapeutic
window  for  further  clinical  application.  Live  corneas
transduced  by  rAV  were  visualized  under  a  fluorescent
microscope and periodically photographed; following rAAV
transduction, it was not possible to detect fluorescent signal
from live corneas. At the end of the experiment corneas were
cut in half and embedded in OCT without fixation. For rAV,
cryostat  sections  were  examined  by  direct  fluorescence
microscopy. For rAAV, sections were fixed in 2% formalin
for  5  min  and  subjected  to  indirect  immunofluorescent
staining with two different antibodies to GFP (rabbit ab6662;
Abcam, Cambridge, MA, and mouse MAB3580; Millipore,
Billerica, MA). Secondary cross-species adsorbed antibodies
were  from  Jackson  ImmunoResearch  Laboratories  (West
Grove,  PA).  To  assess  the  specificity  of  GFP  antibodies,
sections  of  organ-cultured  corneas  not  exposed  to  GFP
expressing vectors were stained.
RESULTS
Rabbit eyes: Transduction with all rAAV serotypes (type 1,
2, 5, 7, and 8) led to GFP expressions in the rabbit cornea at
seven days post-inoculation as indicated by immunostaining
using the anti-GFP antibody. Representative images of GFP
staining  from  rabbits’  eyes  treated  with  different  AAV
serotypes  as  well  as  control  eyes  are  shown  in  Figure  2.
Substantial staining was observed in all cell types including
epithelium, keratocytes and endothelium. The expression of
GFP was not limited to the cells in the area covered by the
trephine. No substantial difference was noticed in the GFP
expression level along the corneal sections that included the
limbal region. The wounded area could not be detected in the
sections; therefore, the “renewed” or healed epithelium could
not be distinguished from the epithelium in the noninjured
area. However, transgene expression was detected throughout
the corneal epithelial cell layers when the injury had healed.
These results suggest that the rAAV vectors transduced both
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the  basal  epithelial  cells,   and  the  cells  that  were  outside
of the wound area.
All rAAV serotypes transduced the corneal epithelial cell
layer and produced GFP expression that was significantly
(p=0.007)  above  levels  in  non-transduced  corneas
(background). Relative GFP immunostaining intensities in
corneal  epithelium  from  different  rAAV  serotypes  are
presented in Figure 1. Statistical analysis showed that rAAV1
yielded significantly higher GFP expression than rAAV5 (2.2
fold; p=0.03), with a trend (p=0.09) for higher expression than
rAAV7, but was not significantly different from rAAV2 or
rAAV8. There was also a trend for rAAV8 GFP expression to
be higher than rAAV5 GFP expression (p=0.09).
GFP expression in the stromal and endothelial layers of
corneas transduced by all five rAAV serotypes was less than
that  observed  in  the  epithelial  cell  layers.  To  increase
sensitivity of detection, confocal microscopy was performed
on  immunostained  sections  using  alkaline  phosphatase-
conjugated  secondary  antibody  with  the  fluorescent
VectorRed® substrate. As shown in Figure 3, transduction
with rAAV5 generated distinct immunostaining of stromal
keratocytes and endothelial cells compared to non-transduced
corneas. In contrast, transduction with rAAV1 and especially
rAAV8  produced  substantially  weaker  immunostaining  of
keratocytes and endothelial cells (Figure 2).
Organ culture: GFP expression was also studied in rAAV-
infected organ-cultured human normal and diabetic corneas.
As in rabbit eyes, the signal intensity was low at both 14 and
23  days  and  could  not  be  reliably  detected  with  direct
fluorescence microscopy. Immunohistochemistry with anti-
GFP antibodies, however, allowed easy detection of the GFP
signal (Figure 4). Epithelial cells were uniformly stained; only
with rAAV1 the staining of basal cells was more pronounced
than of other epithelial layers. At over three weeks, epithelial
staining was somewhat stronger than at two weeks (Figure 4,
compare top and bottom). In addition, positive staining of
most or all keratocytes and endothelial cells was evident with
all serotypes, in accordance with rabbit corneas (Figure 4).
Normal and diabetic corneas showed no difference in GFP
intensity and distribution (data not shown).
Organ-cultured corneas were additionally used to study
GFP  expression  after  infection  with  rAV-GFP.  Direct
fluorescence microscopy of live corneas five days after rAV-
GFP  treatment  revealed  strong  signal  in  the  epithelium
(Figure 5, upper left). The signal intensity correlated with the
dose of the virus (data not shown). On corneal sections, GFP
was clearly expressed in all epithelial layers; some negative
cells were also seen (Figure 5, upper right). Most keratocytes
were negative but some endothelial cells were positive (Figure
5,  lower  row).  The  expression  of  GFP  after  rAV-GFP
infection was observed for more than one month and started
declining thereafter, consistent with previous data [44].
DISCUSSION
Adenoviral, adeno-associated, and lentiviral vectors have
been studied extensively for gene therapy. Currently, their
Figure 2. Immunostaining of rabbit corneas for GFP expression delivered by different serotypes of rAAV vectors, using the streptavidin-
peroxidase detection system. e, epithelium; s, stroma; en, endothelium. Bar=80 μm.
Molecular Vision 2008; 14:2087-2096 <http://www.molvis.org/molvis/v14/a245> © 2008 Molecular Vision
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targeting, development of immune reactions (rAV, rAAV),
and random integration into the host genome (lentiviruses)
sometimes resulting in serious side effects [45,46]. However,
corneal  immune  privilege  makes  it  a  potentially  safe  and
promising  site  for  viral  gene  therapy.  This  is  particularly
relevant for rAV [47]. In case of rAAV, there is an added
advantage that the virus is non-pathogenic and is able to more
Figure 3. rAAV-GFP transduction of rabbit corneas. Upper row, rAAV-GFP5; strong signal is seen in the epithelium (e), stromal cells (s),
and endothelium (en). Epithelial, stromal, and endothelial cells are positive for GFP after rAAV treatment. Lower row, untreated rabbit corneas
as a negative control showing background fluorescence. DM indicates Descemet’s membrane. GFP was visualized using confocal microscopy
and alkaline phosphatase fluorescent detection system. Bar=20 μm.
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An important question in viral gene therapy remains the vector
tropism for different cells and a possibility of infecting only
their specific subsets.
The data presented here suggest that both rAV and rAAV
may be used to successfully deliver genes of interest into
human corneas. The rAAV data on organ-cultured human
corneas including GFP distribution patterns and the necessity
of using immunostaining to detect signal are very similar to
our results obtained with the in vivo rabbit corneas (compare
Figure 3 with Figure 4). rAAV may have some advantage over
rAV in terms of longer persistence in vivo of delivered gene’s
expression [48]. Moreover, as shown here, it was able to
deliver the reporter gene into epithelial cells, keratocytes, and
endothelium. The extensive transduction of all three layers of
the cornea is likely to be due to the use of the vacuum trephine.
Compared to previous studies, it ensured longer exposure of
the rAAV vectors to the corneal cells at the ablation site. We
have had only minimal success in transducing rabbit corneal
cells after ablation unless the contact time on the corneal
surface was prolonged through the use of the vacuum trephine.
Just putting eye drops containing a rAAV vector on the rabbit
cornea  after  ablation  does  not  produce  high  levels  of
transduction of corneal cells.
Transduction  of  the  rabbit  corneas  with  rAAV8  and
especially, rAAV1, produced a stronger GFP expression in
epithelial cells compared to rAAV5. The stronger transgene
expression with rAAV1 compared to rAAV5 was similar to
previous data on transduction of erythropoietin gene into the
retina  with  subretinal  injection,  and  on  transduction  of
apolipoprotein  A-IMilano  with  intramuscular  or  intravenous
injection [31,49]. At the same time, rAAV1 yielded relatively
less GFP expression in stromal keratocytes and endothelial
cells than rAAV2 and rAAV5. These results could be due to
different tropism of the rAAV serotypes for the three corneal
cell types, similar to the situation in retina [31]. Serotype
differences in stromal and endothelial transduction were not
obvious  in  organ  cultures,  which  could  be  due  to  easier
accessibility of these cells to the virus. Our results agree with
previous data showing that rAAV serotypes 1–5 ensured equal
levels of transduction in cultured cells, but in vivo (liver and
muscle) there were significant differences among serotypes in
terms of gene expression levels [35].
The delivery method of rAAV vector in our in vivo study
does not rely on injection into the cornea, which is painful and
can cause damage to corneal structure. Our positive results
with rAAV infection of corneal organ cultures suggest that in
vivo gene transfer via rAAV may not even necessitate prior
epithelial removal. Further studies need to be conducted to
compare the penetration ability of each serotype of rAAV and
duration of gene expression in vivo. The small sample number
(two  eyes  of  one  rabbit)  in  each  treatment  may  limit  the
representation of the observation, although it was consistent
between  serotypes.  Future  experiments  to  observe  rAAV
transgene expression at a longer period will provide more
information. In addition, since self-complementary rAAV has
been shown to lead to earlier expression of passenger genes,
it might be useful to test this vector in the cornea.
Figure 4. rAAV-GFP transduction of organ-cultured human normal and diabetic corneas. Virus serotypes 1, 2, and 8 were used. Upper row
– staining with mouse a-GFP MAB3580 (right panel – staining of an organ-cultured cornea not exposed to rAAV-GFP [negative control] with
the same antibody [mouse a-GFP]); lower row – staining with rabbit a-GFP antibody ab6662 (right panel – staining of another negative control
cornea with antibody ab6662 [rabbit a-GFP]). Epithelial (e), stromal (s), and endothelial (inset panels) cells are well transduced by rAAV-
GFP. No staining is seen in corneas not exposed to the GFP-expressing virus. Both antibodies give very similar patterns. GFP was revealed
by indirect immunofluorescent staining. DM, Descemet’s membrane. Bar=40 μm.
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corneal epithelium, with less signal seen in corneal endothelial
cells.  Generally,  there  was  no  signal  in  keratocytes.  The
immunostaining was corroborated by quantitative RT–PCR
after infection of organ-cultured corneas with rAV harboring
c-met  gene.  Its  expression  was  upregulated  in  isolated
epithelial cells 2.3 fold on average (n=3) but stayed the same
in the stromal cells (data not shown). GFP expression level
was  significantly  higher  with  rAV  than  with  rAAV.  In
agreement with our results, investigators observed that GFP-
positive  cells  had  a  restricted  distribution  in  the  stroma
following intrastromal injection of rAV, and there was no
transfection of the epithelium or endothelium [50]. Our results
differ from the in vivo rat model [33] in that in organ culture,
more epithelial cells were transduced and endothelial cells
were also positive. This is probably due to a much longer
exposure  to  the  virus  in  vitro  and  accessibility  of  the
endothelial cells to rAV in the organ culture system.
Depending on whether the expression level or the ability
to reach more corneal cells is more important, rAV or rAAV
Figure 5.  rAV-GFP transduction of organ-cultured  normal corneas.  Upper left, live cornea;  other panels, transverse corneal sections
(combined fluorescence and transmitted light)
stromal keratocytes (C) are negative. e, epithelium; s, stroma; DM, Descemet’s membrane. Direct fluorescence. Bar=20 μm.
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.  Mostly  edithelial  (A,B)  and  some endothelial cells (D)  are  transgene-positive,  whereasmay  be  chosen  for  specific  purposes  of  gene  transfer  to
corneas. For instance, keratoconus is significantly associated
with stromal changes [51,52], and potential gene therapy may
use rAAV to target keratocytes. In case of diabetic corneas,
where most abnormalities are associated with the epithelium
[53], or if there is need for high levels of transgene expression,
rAV may become a vector of choice as a gene therapy vehicle.
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